dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Bratland, Åse |
dc.contributor.author | MORTIER, Laurent |
dc.contributor.author | Roshdy, Osama |
dc.contributor.author | González, Rene |
dc.contributor.author | Schachter, Jacob |
dc.contributor.author | MUÑOZ COUSELO, EVA |
dc.date.accessioned | 2023-12-20T11:32:39Z |
dc.date.available | 2023-12-20T11:32:39Z |
dc.date.issued | 2023-12 |
dc.identifier.citation | Bratland Å, Munoz-Couselo E, Mortier L, Roshdy O, González R, Schachter J, et al. Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629. Dermatol Ther (Heidelb). 2023 Dec;13:3165–80. |
dc.identifier.issn | 2193-8210 |
dc.identifier.uri | https://hdl.handle.net/11351/10733 |
dc.description | Carcinoma de cèl·lules escamoses avançat; Immunoteràpia; Pembrolizumab |
dc.description.sponsorship | Funding for this research and the journal’s Rapid Service Fee was provided by Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Dermatology and Therapy;13 |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Anticossos monoclonals - Ús terapèutic |
dc.subject | Pell - Càncer - Tractament |
dc.subject | Qualitat de vida |
dc.subject.mesh | Quality of Life |
dc.subject.mesh | Carcinoma, Squamous Cell |
dc.subject.mesh | Skin Neoplasms |
dc.subject.mesh | Antibodies, Monoclonal |
dc.title | Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629 |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s13555-023-01059-y |
dc.subject.decs | calidad de vida |
dc.subject.decs | carcinoma de células escamosas |
dc.subject.decs | neoplasias cutáneas |
dc.subject.decs | anticuerpos monoclonales |
dc.relation.publishversion | https://doi.org/10.1007/s13555-023-01059-y |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Bratland Å] Head and Neck Oncology, Oslo University Hospital, Oslo, Norway. [Munoz-Couselo E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Melanoma and Other Cutaneous Tumours Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Mortier L] Department of Dermatology, INSERM U 1189, Université Lille, Centre Hospitalier Regional Universitaire de Lille, Lille, France. [Roshdy O] Division of Dermatology, McGill University, Canada. [González R] Surgical Oncology, Centro Estatal de Cancerologiade Chihuahua, Chihuahua, Mexico. [Schachter J] Division of Oncology, Cancer Center (Oncology Institute), Sheba Medical Center–Tel Hashomer, Ramat Gan, Israel |
dc.identifier.pmid | 37943491 |
dc.identifier.wos | 001100005100001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |